2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06G.02 Profiling the Metastatic Potential of Non-Small Cell Lung Cancer Patients Based on TP53 Classification

EP.06G.02 Profiling the Metastatic Potential of Non-Small Cell Lung Cancer Patients Based on TP53 Classification

Pdf Summary

Jun Lu, an Associate Professor at the Shanghai Chest Hospital, led a study examining the metastatic potential of non-small cell lung cancer (NSCLC) related to TP53 gene classification. The study involved 2,736 patients with stages I to IV NSCLC, using next-generation sequencing (NGS) to analyze tissue samples targeting 68 cancer-related genes. The research aimed to determine the contribution of TP53 mutations and co-mutations to the metastatic potential of the cancer.<br /><br />Participants were divided based on their TP53 mutation status across various NSCLC histopathological subtypes. The study categorized patients into four cohorts: TP53 (Low), TP53 (Medium), TP53 (High), and LUSC (lung squamous cell carcinoma) based on mutation frequency. Notably, more malignant pathological subtypes exhibited higher frequencies of TP53 mutations. For instance, poorly differentiated, metastatic LUAD, and mixed LUAD/LUSC cases had TP53 mutation rates as high as 68-74%, while LUSC subtypes had even higher rates, reaching up to 95%.<br /><br />The analysis highlighted that unique combinations of TP53 co-mutations elevate metastatic potential. In LUAD, combinations like RB1ATM, KRASSTK11, and EGFRKRAS were significant, whereas PIK3CACDKN2A and FGFR1FGF4 co-mutations were notable for LUSC.<br /><br />Conclusively, the study underscored that TP53 co-mutations are pivotal in determining NSCLC's metastatic potential, suggesting that these genetic profiles could be targeted for better therapeutic strategies. The findings emphasize the role of driver gene patterns in enhancing the metastasizing capability of tumors, particularly in patients harboring TP53 mutations.

Asset Subtitle

Jun Lu

Meta Tag

Speaker Jun Lu

Topic Pathology and Biomarkers

Keywords

NSCLC

TP53 mutations

metastatic potential

next-generation sequencing

lung cancer

co-mutations

histopathological subtypes

LUAD

LUSC

therapeutic strategies